DDInter458 DDInter640
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of the lung. On June 27, 2018, the Food and Drug Administration approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Cyclosporine {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Encorafenib
Cyclosporine {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Secobarbital
Secobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Cyclosporine {u} (Compound) causes {v} (Side Effect) Encephalopathy
Encephalopathy {u} (Side Effect) is caused by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Encorafenib
Cyclosporine {u} (Compound) causes {v} (Side Effect) Encephalopathy
Encephalopathy {u} (Side Effect) is caused by {v} (Compound) Ezogabine
Ezogabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Cyclosporine {u} (Compound) causes {v} (Side Effect) Encephalopathy
Encephalopathy {u} (Side Effect) is caused by {v} (Compound) Phenytoin
Phenytoin {u} may lead to a major life threatening interaction when taken with {v} Encorafenib
Cyclosporine {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Chloramphenicol
Chloramphenicol {u} may lead to a major life threatening interaction when taken with {v} Encorafenib
Cyclosporine {u} (Compound) upregulates {v} (Gene) SLC1A4
SLC1A4 {u} (Gene) is upregulated by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Encorafenib
Cyclosporine {u} (Compound) downregulates {v} (Gene) PCNA
PCNA {u} (Gene) is downregulated by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Encorafenib
Cyclosporine {u} (Compound) upregulates {v} (Gene) SLC1A4
SLC1A4 {u} (Gene) is upregulated by {v} (Compound) Clofarabine
Clofarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Cyclosporine {u} (Compound) downregulates {v} (Gene) PCNA
PCNA {u} (Gene) is downregulated by {v} (Compound) Chlorpromazine
Chlorpromazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Cyclosporine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Cyclosporine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Secobarbital (Compound) and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Cyclosporine (Compound) causes Encephalopathy (Side Effect) and Encephalopathy (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Cyclosporine (Compound) causes Encephalopathy (Side Effect) and Encephalopathy (Side Effect) is caused by Ezogabine (Compound) and Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Cyclosporine (Compound) causes Encephalopathy (Side Effect) and Encephalopathy (Side Effect) is caused by Phenytoin (Compound) and Phenytoin may lead to a major life threatening interaction when taken with Encorafenib
Cyclosporine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Chloramphenicol (Compound) and Chloramphenicol may lead to a major life threatening interaction when taken with Encorafenib
Cyclosporine (Compound) upregulates SLC1A4 (Gene) and SLC1A4 (Gene) is upregulated by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Cyclosporine (Compound) downregulates PCNA (Gene) and PCNA (Gene) is downregulated by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Cyclosporine (Compound) upregulates SLC1A4 (Gene) and SLC1A4 (Gene) is upregulated by Clofarabine (Compound) and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Cyclosporine (Compound) downregulates PCNA (Gene) and PCNA (Gene) is downregulated by Chlorpromazine (Compound) and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib